Astro Bug

CRANBURY, N.J. - AstroBug -- The commencement of patient dosing in the Phase 1/2 trial represents a significant advancement in IVIEW Therapeutics' mission to develop innovative solutions for individuals suffering from dry eye disease, particularly those inadequately managed by artificial tears. This first-in-human (FIH) trial aims to rigorously assess the safety, tolerability, and preliminary efficacy of IVW-1001.

Dry eye disease is a prevalent and burdensome condition affecting millions worldwide. IVW-1001, developed by IVIEW Therapeutics, offers promising potential as a therapeutic intervention through its TRPM8 agonist mechanism, targeting the underlying causes of dry eye. The innovative delivery route via an ophthalmic eyelid wipe further distinguishes IVW-1001 as a potentially groundbreaking treatment.

More on Astro Bug

• Security & Compliance on Microsoft 365 Without the Overhead
• Liquid Technologies Announces the Launch of Liquid Studio v21 and Liquid XML Data Binder v21
• From Niche to Necessity: The Curly Coat Movement for Dogs
• Qrybut Successfully Obtains SEC Certification, Bridging Traditional Finance and Digital Assets
• Glisn Launches Revolutionary Cognitive Training App to Combat the Modern Attention Crisis

Houman Hemmati, MD, PhD, Chief Medical Advisor, leading the clinical development of the IVW-1001 program, stated, "Dosing the first patient in our Phase 1/2 clinical trial is an exciting and critical step forward. Our focus remains on thoroughly evaluating the safety and potential efficacy of IVW-1001. This investigational TRPM8 agonist offers an innovative approach to treating dry eye diseases, and we are committed to advancing this program to address the unmet needs of patients worldwide."

Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc., added, "We are thrilled to initiate the clinical development of IVW-1001 with the dosing of our first patient. This milestone underscores our commitment to pioneering treatments for dry eye diseases and highlights the potential of our novel TRPM8 activation mechanism. We look forward to the progress of this trial and the insights it will provide."

About IVIEW Therapeutics Inc.

More on Astro Bug

• Portland's Evolve & Unite Festival Brings a Transformational Experience to the Pacific Northwest
• School Launches 250 Students International Service Trips - Gives $1M to Global Education
• DivX Unveils Enhanced Guide on Converting MOV to MP4 for Effortless Video Conversion
• SourceCode Expands AI Factory Offerings with Atlas AI Ignite at GTC 2025
• Karen Mueller Leads the Charge in Infection Prevention as SterileCare Drives Meaningful Change in Catheter Care

IVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to differentiated products to fulfill unmet medical needs. We invest in novel mechanisms of action, and differentiated drug delivery technology platforms that allow us to bring forward assets with potentially superior target product profiles. The company's innovative portfolio of small molecules and gene therapy assets cover dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. IVIEW is located in Cranbury, New Jersey with 11,045 sq. ft. laboratory and office space in the Princeton area. For additional information, please visit the Company's website at www.iviewtherapeutics.com. For further inquiries or media contacts, please reach out to our team at info@iviewinc.com